Sequoia Capital

Lingyi Bio is a rare disease animal model functional verification platform and gene therapy developer.

Medalion helps hospitals to empower their practice for market expansion while maintaining compliance.

Spectrum Medical is a clinical mass spectrometry product platform that promotes clinical mass spectrometry detection technology to the general public. It has an experienced research and development, operations, and sales team, a standardized GMP production workshop, extensive experience in laboratory construction, and a mature laboratory management system. It provides with complete supporting kits in addition to mastering the core mass spectrometry hardware manufacturing technology and equipment integration development capabilities (maternal and child genetics, nutritional levels, therapeutic drug testing, metabolic monitoring, etc.).

Myome helps identify genes that cause disease and act based on leading science. The data is secure, portable, and reusable throughout life.

DigitAlp is a scientific and technical innovation company devoted to increasing the value of clinical research by giving a fresh perspective-a one-stop digital solution for the whole clinical trial process centred on institutions. Their solution includes an institutional comprehensive management system, the trial electronic medical record system, the sponsor service system, and the subject recruitment and full-service system.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.

Full-Life Technologies Limited is a global company specializing in RadioTherapeutics, with its headquarters in Shanghai, China, and operations extending to Europe. The firm focuses on targeted cancer therapy services within the radiotherapy field, aiming to enhance treatment outcomes for cancer patients. Full-Life is dedicated to advancing nuclear medicine through innovative research in radiopharmaceuticals, which supports healthcare providers in delivering effective cancer treatments.

Our telemedicine platform aims to transform the way healthcare is accessed, offering patients the flexibility to connect with trusted healthcare providers anytime, anywhere. Through our intuitive interface and advanced video conferencing capabilities, we enable seamless communication and personalized care delivery.

Us2.ai is a Singapore-based company that develops artificial intelligence-driven software and digital tools specifically for echocardiography. The company offers online solutions that streamline access to results from echocardiogram analyses and heart ultrasounds. Its machine learning platform automates the traditionally manual process of measuring and interpreting echocardiograms, enhancing the efficiency of cardiovascular research and clinical trials. By providing AI-based decision support tools, Us2.ai aims to save physicians time, improve the accuracy of clinical trials for pharmaceutical companies, and assist in the detection of conditions that are often overlooked or difficult to diagnose in hospital settings.

Hebin Intelligence is an AI ultrasonic medical robot company providing remote ultrasound autonomous ultrasound diagnosis robots.

Kenko Health is focused on creating a health management organization that offers comprehensive healthcare financing services. The company provides all-inclusive individual healthcare plans designed to cover a wide range of medical expenses, including medicines, doctor fees, lab tests, mental health services, dental care, and outpatient hospital bills. By offering low monthly payment options, Kenko aims to make healthcare more affordable for its customers, delivering prepaid benefits and significant discounts on various medical services.

Operator of a health-tech firm intended to help people with their obesity and diabetes and improve their eating habits. The company's application connects users to dietitians for meal plan recommendations as part of a three- or six-month program where users can set their goals, diets, and any diseases that need help with diet and improve nutritional intake, enabling users to lead a healthy lifestyle.

Athelas, Inc. develops and manufactures an innovative in-home blood diagnostic device designed to monitor the immune system using just a drop of blood. Founded in 2016 and based in Mountain View, California, the company's portable optical unit analyzes blood cells and generates diagnostic reports. This technology assists healthcare providers in early identification of conditions such as leukemia, infections, and inflammatory diseases, allowing patients to monitor their immunity levels conveniently from home. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

the first high-tech company in China to focus on the treatment of cerebrovascular disease, it has more than four years of product research and development, leading China's cerebrovascular disease intelligence in an all-around way. vertical field of diagnosis and treatment. It has become a well-known brain stroke intelligence diagnosis and treatment platform in China.

NeuroXess is an invasive brain-computer interface with high-density flexible brain electrodes aimed at brain research and disease diagnosis.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic company established in 2019 and headquartered in Suzhou, China, with a research and development office in Singapore. The company specializes in developing advanced diagnostic technologies aimed at infectious diseases, cancer, and chronic diseases. Its offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Through these technologies, Virtue Diagnostics aims to enhance disease detection and management, contributing to improved healthcare outcomes.

Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., founded in 2012 and located in Zhengjiawu, China, specializes in researching and developing innovative drugs for metabolic diseases and breast cancer. The company focuses on addressing conditions such as Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes, and colon cancers. By concentrating on metabolism and inflammation, Atom Bioscience aims to provide more effective treatment options for patients suffering from these ailments, enhancing the quality of care in the healthcare sector.

Amador Bioscience, a contract research organization (CRO) that provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.

Vico Medical, established in 2018 and based in Wuhan, China, specializes in the development and production of medical devices aimed at treating cardiovascular and cerebrovascular diseases. The company offers a range of products, including atrial shunts, puncture systems, and occluders for patent foramen ovale, along with delivery systems and other related devices. Vico Medical focuses on providing innovative intervention treatment solutions for structural cardiovascular issues, contributing to the reduction of stroke and heart-related disease incidents.

Shanghai Duoning Biotechnology Co., Ltd. specializes in the development of serum-free, personalized, and chemically defined cell culture media for the biopharmaceutical industry. Founded in 2005 and based in Shanghai, the company offers a range of products, including basic media, feed media, and cell therapy media. Duoning Biotech is dedicated to providing tailored media development, cell culture process optimization, and commissioned formula production services, utilizing its expertise in animal cell culture concepts. The company supports the research, development, and commercialization of biologics products by delivering comprehensive solutions that encompass technical support and customized services tailored to the needs of pharmaceutical and scientific research institutions.

Mosaic Wellness Pvt Ltd, founded in 2019 and based in Mumbai, India, operates a platform of digital-first health clinics aimed at enhancing the health and wellness of individuals. The company provides a range of health and wellness products through its online presence, focusing on personalized solutions for specific needs. Its brands, including ManMatters for men and BeBodywise for women, work collaboratively to promote a fulfilling and purposeful lifestyle. By addressing niche segments, Mosaic Wellness strives to empower individuals to lead healthier lives.

Medalion helps hospitals to empower their practice for market expansion while maintaining compliance.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Twin Health is a Precision Health platform combining IoT Sensors, Machine Learning, and Medical Science to improve human metabolic health. It was founded by experienced entrepreneurs with extensive experience building software platforms used by more than 100 million devices around the world. They are backed by leading VC firm Sequoia Capital and private investors with $43M in Series A and Series B funding. At Twin, they have developed unique patent-pending technology (5 patents filed) to analyze complex biosignals from wearable sensors, predict metabolic outcomes using ML, and recommend highly-personalized treatments based on the metabolic profile of each patient. They launched their product in India in 2018 with an initial focus on diabetes; doctors and coaches use our IoT- and ML-based software platform to improve the health of diabetic patients every day.

TRIALSPARK, INC. develops health tech platform. Its platform provides clinical trial sites with monetary compensation, medication, study visits, and study-related tests and procedures. The company was incorporated in 2013 and is based in New York, New York.

Developer of gene sequencing technology designed to promote the development of precision medicine. The company's business scope covers software and hardware for sequencers, sample processing, consumables, reagents and data processing, enabling genetic sequencing to be a routine detection and diagnostic tool for medical industry.

Amador Bioscience, a contract research organization (CRO) that provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.

Operator of a health-tech firm intended to help people with their obesity and diabetes and improve their eating habits. The company's application connects users to dietitians for meal plan recommendations as part of a three- or six-month program where users can set their goals, diets, and any diseases that need help with diet and improve nutritional intake, enabling users to lead a healthy lifestyle.

Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.

Westlake Therapeutics is a biopharmaceutical company based in Hangzhou, China, founded in 2019. The company specializes in cell therapy, focusing on developing engineered Red Blood Cells (RBC) through its REDx platform. This innovative technology aims to treat a wide range of human diseases, including cancers, immunological and metabolic disorders, and rare diseases. By utilizing genetic engineering techniques on hematopoietic stem and progenitor cells sourced from peripheral blood, bone marrow, or cord blood, Westlake Therapeutics seeks to provide personalized and effective treatment options for patients, advancing the field of cellular medicine.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

MoonBiotech is a Guangzhou-based healthcare startup that focuses on the development and research of microbe-based bioactive products for diverse applications. The company specializes in creating and screening high-quality microbial ingredients and fermentation products, catering to the needs of various industries such as biological agriculture, environmental governance, health food, and biomedicine. By providing valuable microbiological resources, MoonBiotech aims to address the increasing demand for innovative solutions in these sectors.

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Analytical Biosciences focuses on the development of single-cell genome technologies to enhance the understanding and treatment of human diseases. By collaborating with medical research institutions, hospitals, and pharmaceutical companies, the company leverages single-cell genomics and bioinformatics to create detailed maps of diseases. This approach allows for large-scale systematic disease mapping and the mining of extensive data sets, which aids partners in identifying new therapeutic targets and formulating innovative treatment strategies. Analytical Biosciences employs high-resolution databases and advanced data analytics to facilitate the discovery and validation of novel cellular targets and biomarkers, ultimately contributing to the development of next-generation therapeutics and diagnostics.

Noom, Inc. is a mobile health coaching company that focuses on preventing and managing chronic conditions such as obesity, diabetes, and hypertension. Founded in 2008 and headquartered in New York, with additional offices in Seoul and Tokyo, Noom combines technology with human empathy to facilitate behavior change. Its platform includes evidence-based curricula, trained cognitive behavior coaches, and mobile tracking tools, allowing users to engage in personalized health management. Noom's direct-to-consumer applications have successfully reached over 47 million users globally, and the company has expanded its offerings to include programs for pre-hypertension and diabetes management, as well as its original weight loss initiatives. By leveraging the recognition from the CDC's Diabetes Prevention Program, Noom aims to provide scalable solutions for individuals seeking to improve their health outcomes.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.

Connect Medical Value is a company that creates mobile apps for physicians. Founded in 2020 and is based in Hangzhou, Zhejiang, China.

Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Novotech is Australia’s largest independent CRO. The Australian Head Office is in Sydney, with regional offices in Melbourne and Brisbane - providing easy access to the most important population centers in Australia. Supported by regional staff across the country and in New Zealand, our coverage of the Australia/New Zealand region is comprehensive. With Asian services launched in 2007, Novotech’s operations provide access to the most dynamic and fast growing clinical research hubs in the region.

Jifan Biotechnology is a biotechnology firm that provides molecular biology reagents, diagnostic raw materials, and kits for research.

WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.

NuProbe, Inc. is an early-stage molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and based in Cambridge, Massachusetts, with an additional office in Shanghai, China, the company has developed a unique platform utilizing genetic toehold probes for quantitative PCR (qPCR) mutation detection. This innovative probe technology offers a Sample-In Answer-Out (SIAO) solution that integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatics interpretations, streamlining the diagnostic process.

Insight Lifetech Co., Ltd. is a Chinese company focused on the development and manufacturing of medical equipment for heart intervention. The firm specializes in creating high-quality devices designed to enhance the diagnosis and therapy of cardiovascular diseases. By utilizing innovative technologies, Insight Lifetech aims to provide reliable precision in medical treatments, ultimately enabling healthcare professionals to save and improve patients' lives.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Virta Health operates an online specialty medical clinic focused on reversing type 2 diabetes without the use of medications or surgery. Founded in 2014 and based in San Francisco, the company combines nutritional biochemistry, clinical expertise, data science, and digital tools to develop its treatment protocols. Through its continuous remote care platform, Virta provides medical and behavioral support to patients, resulting in significant health improvements. In clinical trials, 60% of participants achieved diabetes reversal within one year, and 94% of insulin users were able to reduce or eliminate their insulin usage. The benefits of Virta's treatment extend to other aspects of metabolic and cardiovascular health, demonstrating sustained improvements in blood pressure, inflammation, liver function, and body mass index (BMI).

D3 Bio Inc. is a biotechnology company founded in 2020 and based in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company adopts a unique approach to medicine development by first identifying significant unmet patient and market needs, particularly in areas where current treatments are inadequate. This understanding informs their research and guides the selection of appropriate scientific and technological methods to define their drug development strategy. Through this differentiated approach, D3 Bio aims to address critical health challenges and improve clinical outcomes for patients.

Twin Health is a Precision Health platform combining IoT Sensors, Machine Learning, and Medical Science to improve human metabolic health. It was founded by experienced entrepreneurs with extensive experience building software platforms used by more than 100 million devices around the world. They are backed by leading VC firm Sequoia Capital and private investors with $43M in Series A and Series B funding. At Twin, they have developed unique patent-pending technology (5 patents filed) to analyze complex biosignals from wearable sensors, predict metabolic outcomes using ML, and recommend highly-personalized treatments based on the metabolic profile of each patient. They launched their product in India in 2018 with an initial focus on diabetes; doctors and coaches use our IoT- and ML-based software platform to improve the health of diabetic patients every day.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Biofourmis Singapore Pte. Ltd. is a digital therapeutics company that focuses on enhancing personalized care through innovative software-based solutions. Founded in 2015, it operates from its headquarters in Boston, Massachusetts, with additional offices in Singapore, Zurich, and Bengaluru. The company’s platform integrates artificial intelligence to analyze real-time physiological data from clinical-grade wearables, enabling healthcare professionals to detect patterns and predict medical events, such as heart failure and oncology-related issues. Its product offerings include BiovitalsHF for early heart failure detection, RhythmAnalytics for cardiac arrhythmia monitoring, and Painfocus for objective pain assessment, aimed at improving therapeutic decision-making. Additionally, Biofourmis provides Gaido for oncology patient monitoring and Biovitals Research, a digital trial platform that enhances patient engagement and data collection. Through these solutions, Biofourmis aims to facilitate better patient outcomes and cost-effective care for healthcare providers.

Dizal Pharmaceutical is a research-focused biotechnology company involved in the discovery, development, and commercialization of innovative medicines. The company specializes in creating first-in-class and best-in-class therapeutic solutions, emphasizing cutting-edge research and development. In addition to its drug development efforts, Dizal is also engaged in the production and sales of these innovative treatments, aiming to improve patient outcomes through advanced pharmaceutical solutions.

Practo Technologies Private Limited operates a comprehensive healthcare platform that connects patients with healthcare providers globally. Established in 2008 and headquartered in Bengaluru, India, Practo offers a range of services to meet diverse healthcare needs, including finding doctors, booking appointments, accessing online consultations, scheduling diagnostic tests, and ordering medicines. The platform also features Practo Ray, a subscription-based practice management software for healthcare professionals, and Practo Reach, a service that enhances visibility for hospitals and clinics. With additional offices in major Indian cities and locations in Southeast Asia and Brazil, Practo aims to facilitate better healthcare management by allowing users to store health records, consult doctors online, and engage with healthcare services more effectively.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Twin Health is a Precision Health platform combining IoT Sensors, Machine Learning, and Medical Science to improve human metabolic health. It was founded by experienced entrepreneurs with extensive experience building software platforms used by more than 100 million devices around the world. They are backed by leading VC firm Sequoia Capital and private investors with $43M in Series A and Series B funding. At Twin, they have developed unique patent-pending technology (5 patents filed) to analyze complex biosignals from wearable sensors, predict metabolic outcomes using ML, and recommend highly-personalized treatments based on the metabolic profile of each patient. They launched their product in India in 2018 with an initial focus on diabetes; doctors and coaches use our IoT- and ML-based software platform to improve the health of diabetic patients every day.

Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.

Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., founded in 2012 and located in Zhengjiawu, China, specializes in researching and developing innovative drugs for metabolic diseases and breast cancer. The company focuses on addressing conditions such as Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes, and colon cancers. By concentrating on metabolism and inflammation, Atom Bioscience aims to provide more effective treatment options for patients suffering from these ailments, enhancing the quality of care in the healthcare sector.

Healthlane is a healthcare technology company that operates an online application aimed at enhancing access to quality and affordable healthcare services in Africa. Established in 2020 and headquartered in Lagos, Nigeria, with additional offices in Yaounde, Cameroon, and San Francisco, California, the platform facilitates users in tracking medical appointments and consolidating their health data. It offers features such as virtual medical advice on various health topics, including pregnancy, vaccinations, lab results, family planning, and insurance records. By enabling direct communication with certified doctors, Healthlane empowers individuals to make informed health decisions and efficiently monitor their health status.

MedGenome Labs Private Ltd. specializes in molecular genetic diagnostic testing, utilizing advanced technologies such as Sanger sequencing and next-generation sequencing to support personalized healthcare. The company offers a comprehensive range of genetic tests, including exome, whole genome, and mitochondrial genome sequencing, alongside various disease panels. These panels focus on hereditary cancers, somatic mutations in tumors, and genetic conditions affecting cardiac, eye, and neuromuscular health. Additionally, MedGenome provides targeted tests for genetic mutations linked to non-syndromic deafness and autism spectrum disorders. The company also maintains OncoMD, a database of cancer-related mutations sourced from peer-reviewed research. MedGenome's services are designed to guide clinicians in identifying appropriate treatment options based on genetic variations and assessing disease risk. Established in 2013 and headquartered in Chennai, India, MedGenome operates as a subsidiary of SciGenom Labs Pvt Ltd and collaborates strategically with Denali Therapeutics to enhance its research capabilities.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

Eko.ai Pte. Ltd. is a Singapore-based company that specializes in artificial intelligence software aimed at the early detection and treatment of heart disease. Founded in 2017, the company focuses on democratizing echocardiography and ultrasound imaging to enhance cardiovascular risk assessment. Eko.ai employs machine learning to automate processes, providing research teams with fully classified, machine learning-ready databases and a variety of tools, including segmentation and validation models. By collaborating with clinician scientists, sonographers, and deep learning experts, Eko.ai serves laboratories worldwide, aiming to improve productivity and patient outcomes within hospital systems.

RootPath Genomics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. The company specializes in developing a personalized T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of single immune cells, RootPath aims to enhance the understanding of anti-tumor immunity. Their innovative technologies enable drug developers, physicians, and patients to monitor, modulate, and direct the immune system, facilitating advancements in the diagnosis and treatment of cancer.

Developer of dental imaging technology and dental clinic management software. The company's software helps dental professionals accurately diagnose patient conditions through oral CT scanning, as well as keep track of patient records and appointments, enabling dental professionals to provide treatment more efficiently.

Mosaic Wellness Pvt Ltd, founded in 2019 and based in Mumbai, India, operates a platform of digital-first health clinics aimed at enhancing the health and wellness of individuals. The company provides a range of health and wellness products through its online presence, focusing on personalized solutions for specific needs. Its brands, including ManMatters for men and BeBodywise for women, work collaboratively to promote a fulfilling and purposeful lifestyle. By addressing niche segments, Mosaic Wellness strives to empower individuals to lead healthier lives.

Path is a comprehensive addiction treatment solution designed for employers and organizations, focusing on the treatment and management of Substance Use Disorder (SUD) for employees and their families. The company collaborates with experienced healthcare professionals and visionaries to deliver scientifically validated treatment for SUD on a large scale. Path aims to provide an affordable and accessible approach to managing addiction as a chronic illness, ensuring that individuals have the necessary resources to address their needs effectively. Through its innovative solutions, Path seeks to improve the overall well-being of employees while supporting organizations in fostering a healthier workforce.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Yuanxin Huibao is a health insurance technology service provider. It provides insurance for health care in major areas such as major diseases and chronic diseases. It provides users with more reliable medical and medical services and is more insurance. The company offers solutions such as “product actuarial pricing, risk control, user acquisition and viscosity”.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.

Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.

Biofourmis Singapore Pte. Ltd. is a digital therapeutics company that focuses on enhancing personalized care through innovative software-based solutions. Founded in 2015, it operates from its headquarters in Boston, Massachusetts, with additional offices in Singapore, Zurich, and Bengaluru. The company’s platform integrates artificial intelligence to analyze real-time physiological data from clinical-grade wearables, enabling healthcare professionals to detect patterns and predict medical events, such as heart failure and oncology-related issues. Its product offerings include BiovitalsHF for early heart failure detection, RhythmAnalytics for cardiac arrhythmia monitoring, and Painfocus for objective pain assessment, aimed at improving therapeutic decision-making. Additionally, Biofourmis provides Gaido for oncology patient monitoring and Biovitals Research, a digital trial platform that enhances patient engagement and data collection. Through these solutions, Biofourmis aims to facilitate better patient outcomes and cost-effective care for healthcare providers.

HealthKart is a company that specializes in health and nutritional supplements for consumers of all age groups. Established in 2011, it has developed into a prominent online destination for fitness enthusiasts, offering a diverse range of products including protein supplements, weight loss solutions, hair care kits, and various health foods and drinks. The company aims to support individuals in achieving their fitness goals by providing quality products and fostering a community for fitness enthusiasts to connect and share their experiences.

Noom, Inc. is a mobile health coaching company that focuses on preventing and managing chronic conditions such as obesity, diabetes, and hypertension. Founded in 2008 and headquartered in New York, with additional offices in Seoul and Tokyo, Noom combines technology with human empathy to facilitate behavior change. Its platform includes evidence-based curricula, trained cognitive behavior coaches, and mobile tracking tools, allowing users to engage in personalized health management. Noom's direct-to-consumer applications have successfully reached over 47 million users globally, and the company has expanded its offerings to include programs for pre-hypertension and diabetes management, as well as its original weight loss initiatives. By leveraging the recognition from the CDC's Diabetes Prevention Program, Noom aims to provide scalable solutions for individuals seeking to improve their health outcomes.

Noom, Inc. is a mobile health coaching company that focuses on preventing and managing chronic conditions such as obesity, diabetes, and hypertension. Founded in 2008 and headquartered in New York, with additional offices in Seoul and Tokyo, Noom combines technology with human empathy to facilitate behavior change. Its platform includes evidence-based curricula, trained cognitive behavior coaches, and mobile tracking tools, allowing users to engage in personalized health management. Noom's direct-to-consumer applications have successfully reached over 47 million users globally, and the company has expanded its offerings to include programs for pre-hypertension and diabetes management, as well as its original weight loss initiatives. By leveraging the recognition from the CDC's Diabetes Prevention Program, Noom aims to provide scalable solutions for individuals seeking to improve their health outcomes.

Noom, Inc. is a mobile health coaching company that focuses on preventing and managing chronic conditions such as obesity, diabetes, and hypertension. Founded in 2008 and headquartered in New York, with additional offices in Seoul and Tokyo, Noom combines technology with human empathy to facilitate behavior change. Its platform includes evidence-based curricula, trained cognitive behavior coaches, and mobile tracking tools, allowing users to engage in personalized health management. Noom's direct-to-consumer applications have successfully reached over 47 million users globally, and the company has expanded its offerings to include programs for pre-hypertension and diabetes management, as well as its original weight loss initiatives. By leveraging the recognition from the CDC's Diabetes Prevention Program, Noom aims to provide scalable solutions for individuals seeking to improve their health outcomes.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Burning Rock Biotech Limited is a cancer diagnostics company based in China that specializes in developing and providing next-generation sequencing (NGS) based cancer therapy selection tests. Founded in 2014 and headquartered in Guangzhou, the company offers a portfolio of 13 tests applicable to various cancer types, including lung, gastrointestinal, and breast cancers, utilizing both tissue and liquid biopsy samples. Notable products include OncoScreen Plus, which targets therapy and immunotherapy biomarkers, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, Burning Rock provides services for gastrointestinal cancer testing and assessments of genes related to homologous recombination deficiency. The company collaborates with major pharmaceutical firms such as AstraZeneca and Bayer on clinical trials and research studies, focusing on companion diagnostics and laboratory services. With a commitment to personalized cancer treatment, Burning Rock aims to deliver comprehensive solutions that integrate genetic testing with clinical and research services.

Health Catalyst is a company that specializes in data and analytics technology for healthcare organizations, addressing the challenges posed by the transition from paper to electronic health records. It focuses on organizing, normalizing, and linking disparate health data from various systems, making it easily searchable for all users, including those without technical expertise. Health Catalyst operates through two primary segments: the Technology segment, which is the main revenue driver, offers cloud-based data platforms, analytics applications, and support services, primarily through subscription and licensing agreements. The Professional Services segment provides a combination of analytics, implementation, strategic advisory, and outsourcing services, helping healthcare organizations effectively utilize the technology to improve outcomes and operational efficiency.

Health Catalyst is a company that specializes in data and analytics technology for healthcare organizations, addressing the challenges posed by the transition from paper to electronic health records. It focuses on organizing, normalizing, and linking disparate health data from various systems, making it easily searchable for all users, including those without technical expertise. Health Catalyst operates through two primary segments: the Technology segment, which is the main revenue driver, offers cloud-based data platforms, analytics applications, and support services, primarily through subscription and licensing agreements. The Professional Services segment provides a combination of analytics, implementation, strategic advisory, and outsourcing services, helping healthcare organizations effectively utilize the technology to improve outcomes and operational efficiency.

Athelas, Inc. develops and manufactures an innovative in-home blood diagnostic device designed to monitor the immune system using just a drop of blood. Founded in 2016 and based in Mountain View, California, the company's portable optical unit analyzes blood cells and generates diagnostic reports. This technology assists healthcare providers in early identification of conditions such as leukemia, infections, and inflammatory diseases, allowing patients to monitor their immunity levels conveniently from home. Athelas operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

Miaoshou Doctor is a healthcare service platform founded in 2015 by Tao He and Daoliang Han, based in Beijing. The platform facilitates communication between healthcare professionals and patients, focusing on the management of post-diagnosis outcomes. It enables doctors to actively follow up with patients through additional counseling and prescriptions, enhancing the overall patient care experience. By providing tools for effective interaction, Miaoshou Doctor aims to improve health management for both patients and doctors.

Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.

Medtrum Technologies Inc. specializes in the development and delivery of medical devices for diabetes management. The company offers a range of products, including the A6 TouchCare System, a tubing-free semi-closed loop insulin management system that integrates an insulin patch pump and continuous glucose monitoring system (CGMS) with predictive low glucose suspend capabilities. Additionally, it provides the S6 EasySense disposable CGM system, which features a waterproof design and a hair-like sensor for real-time glucose monitoring over a week, and the P6 EasyPatch disposable pump that allows for adjustable basal rates and on-demand bolus delivery. Medtrum also incorporates a cloud-based healthcare system, featuring the EasyTouch mobile application and EasyView web portal, which enhances diabetes management by providing comprehensive data for patients, families, and healthcare providers. Founded in 2008 and headquartered in Shanghai, China, Medtrum operates in multiple locations, including Düsseldorf, Germany; Hong Kong; and Watford, United Kingdom.

VoxelCloud Inc. is a company that develops cloud computing and artificial intelligence solutions aimed at enhancing the analysis of medical images and clinical data for healthcare practitioners. Established in 2015 and headquartered in Los Angeles, California, VoxelCloud offers automated medical image analysis services designed to improve clinical workflows and deliver timely insights. The company's technology addresses various clinical needs, including the diagnosis of lung cancer, diabetic retinopathy, coronary heart disease, and liver disease. Utilizing proprietary algorithms and deep learning techniques, VoxelCloud provides accurate and personalized medical image analysis services. In addition to its Los Angeles headquarters, the company has offices in Shanghai and Suzhou, China, along with a satellite research and development team located in Phoenix.

Infervision is an artificial intelligence company based in Beijing that specializes in enhancing medical imaging diagnosis through deep learning and computer vision technologies. The company focuses on developing clinically valuable products aimed at improving the accuracy and efficiency of cancer diagnosis. Infervision has introduced innovative solutions such as the world's first artificial intelligence precise healthcare platform, along with intelligent X-ray and CT diagnostic products, which are currently undergoing trials at several prominent hospitals in China. The company collaborates closely with top institutions in radiology, fostering a strong relationship between medical science and technology. Infervision has partnered with approximately 20 leading hospitals, successfully integrating medical data and technology to advance healthcare solutions. By creating a unique artificial intelligence computing platform, Infervision aims to facilitate precise healthcare and improve diagnostic outcomes for medical professionals.

NextCODE Health LLC is a clinical diagnostics company specializing in sequence-based genomics. It offers a platform that assists healthcare professionals in obtaining clinical insights for rapid disease diagnosis. The company provides a range of services, including data analysis, genome interpretation, data mining, and sequencing services, both clinical and non-clinical. Founded on technology developed at deCODE genetics over 16 years, NextCODE focuses on integrating genome sequence data into patient care. Based in Cambridge, Massachusetts, the company was acquired by WuXi PharmaTech in 2015 and underwent a rebranding to Genuity Science in 2020. Through its innovative solutions, NextCODE aims to enhance the speed and accuracy of identifying genetic causes of diseases.

HealthKart is a company that specializes in health and nutritional supplements for consumers of all age groups. Established in 2011, it has developed into a prominent online destination for fitness enthusiasts, offering a diverse range of products including protein supplements, weight loss solutions, hair care kits, and various health foods and drinks. The company aims to support individuals in achieving their fitness goals by providing quality products and fostering a community for fitness enthusiasts to connect and share their experiences.

TRIALSPARK, INC. develops health tech platform. Its platform provides clinical trial sites with monetary compensation, medication, study visits, and study-related tests and procedures. The company was incorporated in 2013 and is based in New York, New York.

Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company focuses on accelerating the development and commercialization of biotherapeutics and other cell-based products through its integrated platform. This platform includes proprietary consumables, such as OptoSelect chips and reagent kits, along with automation systems and workflow software. Utilizing micro-droplet technology, Berkeley Lights offers research and development services that transform how scientists study cell interactions, significantly enhancing the efficiency of cellular therapies. Their solutions cater to various sectors, including biotherapeutic discovery, cellular therapy manufacturing, synthetic biology, and agricultural biotechnology, helping clients meet the increasing demands of cell-based processes.

Beijing Deep Intelligent Pharma Technology Co., Ltd. specializes in leveraging artificial intelligence and blockchain technology to enhance drug discovery, development, and medical affairs for pharmaceutical companies. Founded in 2017 and based in Beijing, the company offers a range of products, including a multi-language medical machine translation engine, intelligent pharmacovigilance for risk management, and tools for creating multilingual educational materials. Deep Intelligent Pharma also provides AI-enabled solutions for medical writing, document review, and quality control, as well as a patient search ecosystem to facilitate medical and clinical research. Additionally, the company offers intelligent regulatory affairs solutions to streamline drug research and development processes. Operating globally, including in China, the United States, and Japan, Deep Intelligent Pharma aims to improve the efficiency and quality of the pharmaceutical development lifecycle.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.